TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37449421

Group type: EXPERIMENTAL
Intervention: Establishing stroke registers in two large referral hospitals in Tanzania
Number of subjects: 0
Study: 37449423

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37449424

Group type: EXPERIMENTAL
Intervention: CAD alone
Number of subjects: 12856

Group type: EXPERIMENTAL
Intervention: Both CAD and stroke
Number of subjects: 12856

Group type: COMPARATOR
Intervention: Stroke alone
Number of subjects: 12856
Study: 37449426

Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery (AID)
Number of subjects: 10
Study: 37449560

Group type: EXPERIMENTAL
Intervention: ST-segment resolution (STR) ≥50%
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Complete ST-segment resolution (STR)
Number of subjects: 5966

Group type: COMPARATOR
Intervention: STR <50%
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Successful STR and TIMI 3 flow
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Either STR or TIMI flow reduced
Number of subjects: 5966

Group type: EXPERIMENTAL
Intervention: Both STR and TIMI flow abnormal
Number of subjects: 5966
Study: 37449567

Group type: EXPERIMENTAL
Intervention: 30 months of Dual Antiplatelet Therapy (DAPT)
Number of subjects: 1326

Group type: COMPARATOR
Intervention: 12 months of Dual Antiplatelet Therapy (DAPT)
Number of subjects: 1326
Study: 37449568

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 2934

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2934
Study: 37449573

Group type: EXPERIMENTAL
Intervention: Splanchnic nerve modulation (SNM) with ropivacaine
Number of subjects: 15
Study: 37449658

Group type: EXPERIMENTAL
Intervention: Denosumab (120 mg subcutaneously on day 1 of every 4-week cycle, with loading doses of 120 mg on days 8 and 15)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 3
Study: 37449715

Group type: EXPERIMENTAL
Intervention: Pelvic cancer survivors with LRTIs
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Bowel and urinary LRTIs
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Younger survivors, gynecological cancer survivors, or those who received external and internal radiation or additional chemotherapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Sexual health dimensions
Number of subjects: 83
Study: 37449716

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (97/103 mg twice daily)
Number of subjects: 480

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 480
Study: 37449768

Group type: EXPERIMENTAL
Intervention: EMM + $1 per day for perfect medication adherence for 3 months (maximum $84) followed by 1 month of EMM only
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group: EMM with App reminders/feedback for 4 months
Number of subjects: 52
Study: 37449908

Group type: EXPERIMENTAL
Intervention: SEL-212 (ImmTOR 0.15 mg/kg and pegadricase 0.2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegloticase (8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SEL-212 (ImmTOR and pegadricase)
Number of subjects: 0
Study: 37450086

Group type: EXPERIMENTAL
Intervention: NASH-CHECK
Number of subjects: 253
Study: 37450196

Group type: EXPERIMENTAL
Intervention: Fast-acting insulin aspart (faster aspart)
Number of subjects: 178
Study: 37450201

Group type: EXPERIMENTAL
Intervention: cTTP-PEQ
Number of subjects: 36
Study: 37450303

Group type: EXPERIMENTAL
Intervention: Meditation training
Number of subjects: 135
Study: 37450351

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET) + SMAC mimetics
Number of subjects: 0
Study: 37450613

Group type: EXPERIMENTAL
Intervention: 0 h/1 h algorithm
Number of subjects: 5497

Group type: COMPARATOR
Intervention: 0 h/3 h protocol
Number of subjects: 5497

Group type: EXPERIMENTAL
Intervention: Observation group (grey zone) of 0 h/1 h algorithm
Number of subjects: 5497

Group type: EXPERIMENTAL
Intervention: Retrospective analysis of troponin <5 ng/L
Number of subjects: 5497

Group type: EXPERIMENTAL
Intervention: All patients with troponin levels
Number of subjects: 5497
Study: 37450670

Group type: EXPERIMENTAL
Intervention: Intraoperative pudendal nerve block with liposomal bupivacaine
Number of subjects: 83

Group type: COMPARATOR
Intervention: No block
Number of subjects: 83
Study: 37450869

Group type: EXPERIMENTAL
Intervention: Neurocap (bioresorbable nerve capping device)
Number of subjects: 73
Study: 37450935

Group type: EXPERIMENTAL
Intervention: Long-term Doxycycline therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37451283

Group type: EXPERIMENTAL
Intervention: Texture and color enhancement imaging (TXI)
Number of subjects: 747

Group type: COMPARATOR
Intervention: High definition white-light imaging (WLI)
Number of subjects: 747
Study: 37451291

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg intravenously every 6 weeks for up to 18 cycles (2 years) plus lenvatinib 20 mg orally once daily.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib
Number of subjects: 158
Study: 37451295

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 4 weeks for 1 year
Number of subjects: 179

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 179
Study: 37451297

Group type: EXPERIMENTAL
Intervention: Oral lenacapavir (600 mg, days 1 and 2; 300 mg, day 8) followed by subcutaneous lenacapavir 927 mg every 26 weeks
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Optimised background regimen concurrent with lenacapavir (oral to subcutaneous)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo followed by lenacapavir (2-week oral lead-in then subcutaneous)
Number of subjects: 72
Study: 37451339

Group type: EXPERIMENTAL
Intervention: Single-use (SU) ancillaries
Number of subjects: 20
Study: 37451352

Group type: EXPERIMENTAL
Intervention: Moderate uncoupling (Ees/Ea 0.8-1.29)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Severe uncoupling (Ees/Ea < 0.8)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Low hemodynamic risk
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intermediate hemodynamic risk
Number of subjects: 53
Study: 37451355

Group type: EXPERIMENTAL
Intervention: Cardiologist interpretation of point-of-care handheld 1L ECGs
Number of subjects: 15
Study: 37451695

Group type: EXPERIMENTAL
Intervention: Higher neutrophil counts in patients with PD
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Higher neutrophil levels in patients with PD
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Lymphocyte count and NLR in patients with PD
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Neutrophil count in patients with PD
Number of subjects: 376
Study: 37451698

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) measured by three-level EuroQol five-dimension and visual analogy scale at admission, 1 month, 6 months, 12 months, and 10 years follow-up.
Number of subjects: 14899

Group type: EXPERIMENTAL
Intervention: Medications and medication adherence.
Number of subjects: 14899

Group type: EXPERIMENTAL
Intervention: Satisfaction with Information about Medicines Scale and illness perceptions.
Number of subjects: 14899

Group type: EXPERIMENTAL
Intervention: Fatal and non-fatal outcomes following MI.
Number of subjects: 14899
Study: 37451701

Group type: EXPERIMENTAL
Intervention: Bisoprolol (maximum 5 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Celiprolol (maximum 400 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Baseline (post-run-in pooled)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Other non-invasive cardiopulmonary measures
Number of subjects: 11
Study: 37451715

Group type: EXPERIMENTAL
Intervention: Interprofessional care concept developed through mixed-methods design including literature review, qualitative inquiries, and structured workshops.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Survey on collaboration completed by 100 individuals from each group involved in home care.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Monoprofessional focus groups (n=9) of registered nurses, general practitioners, and therapists discussing current practices.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Best practice cases (n=8) analyzed through case-based qualitative content analysis.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mixed focus groups (n=4) with findings from WP2 discussed.
Number of subjects: 100
Study: 37451717

Group type: EXPERIMENTAL
Intervention: Educational and motivational mobile health (mHealth) intervention
Number of subjects: 80000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80000
Study: 37451727

Group type: EXPERIMENTAL
Intervention: Manual therapy program (MTP) consisting of four sessions (once per week) of manual therapy applied to temporomandibular structures.
Number of subjects: 120
Study: 37451728

Group type: EXPERIMENTAL
Intervention: Multidisciplinary combined Exercise and Nutrition Intervention (MENTORS)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Exercise intervention (part of MENTORS)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (part of MENTORS)
Number of subjects: 168
Study: 37451734

Group type: EXPERIMENTAL
Intervention: Locomotor training (LT) paired with transcutaneous spinal cord stimulation (TSCS) for 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Locomotor training (LT) paired with sham stimulation for 12 weeks
Number of subjects: 12
Study: 37451735

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (720 µg/day) and vitamin D3 (25 µg/day) for 2 years
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo treatment (no active treatment) for 2 years
Number of subjects: 400
Study: 37451738

Group type: EXPERIMENTAL
Intervention: Data-to-suppression intervention (D2S) providing surveillance-based reports and capacity-building assistance.
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Control group (delayed implementation of the intervention).
Number of subjects: 1619
Study: 37451740

Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention (4 weeks, 1 weekly session of ~1 to 1.5 hours)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention
Number of subjects: 11
Study: 37451840

Group type: EXPERIMENTAL
Intervention: Automatic oxygen control (A-FiO2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 60
Study: 37451877

Group type: EXPERIMENTAL
Intervention: Flumos-v1 vaccine (tetravalent mosaic influenza nanoparticle vaccine)
Number of subjects: 0
Study: 37451930

Group type: EXPERIMENTAL
Intervention: Atezolizumab, carboplatin, pemetrexed, and bevacizumab
Number of subjects: 117

Group type: COMPARATOR
Intervention: Carboplatin, pemetrexed, and bevacizumab
Number of subjects: 117
Study: 37451932

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Care
Number of subjects: 159

Group type: COMPARATOR
Intervention: Serial Care
Number of subjects: 159
Study: 37452107

Group type: EXPERIMENTAL
Intervention: Adjuvant immune checkpoint inhibitors (ICIs) alone
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Adjuvant immune checkpoint inhibitors (ICIs) with tyrosine kinase inhibitors (TKIs)
Number of subjects: 517

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (either ICIs alone or with TKIs)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Adjuvant immune checkpoint inhibitors (ICIs) alone or with TKIs
Number of subjects: 517
Study: 37452140

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no premedication)
Number of subjects: 90
Study: 37452151

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (DSE)
Number of subjects: 0
Study: 37452167

Group type: EXPERIMENTAL
Intervention: Hard-textured foods
Number of subjects: 18

Group type: COMPARATOR
Intervention: (Ultra)processed soft condition
Number of subjects: 18
Study: 37452174

Group type: EXPERIMENTAL
Intervention: Cabotegravir + Rilpivirine long-acting (CAB+RPV) administered every 2 months (Q2M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily oral single-tablet regimens (STRs)
Number of subjects: 0
Study: 37452196

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO)
Number of subjects: 728

Group type: COMPARATOR
Intervention: Ventilation
Number of subjects: 728
Study: 37452279

Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade (NMB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No neuromuscular blockade (NMB)
Number of subjects: 10
Study: 37452281

Group type: EXPERIMENTAL
Intervention: TaU + MIND (mindfulness-based intervention added to treatment as usual)
Number of subjects: 177

Group type: COMPARATOR
Intervention: TaU (treatment as usual)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: TaU + MIND
Number of subjects: 177

Group type: COMPARATOR
Intervention: TaU
Number of subjects: 177
Study: 37452330

Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.5% three times a day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 37452341

Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil (S-DHA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study: 37452356

Group type: EXPERIMENTAL
Intervention: Unity prosthetic add-on suspension system
Number of subjects: 20
Study: 37452374

Group type: EXPERIMENTAL
Intervention: Tumor-informed methylation-based MRD (timMRD)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Tumor-informed somatic mutation status
Number of subjects: 195
Study: 37452403

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (HND)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Moderate carbohydrate-restricted diet (MCRD)
Number of subjects: 42
Study: 37452428

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) intake
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study: 37452577

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation intervention
Number of subjects: 22
Study: 37452640

Group type: EXPERIMENTAL
Intervention: MTA Angelus
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Total Fill BC
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 137
Study: 37452707

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg subcutaneous within 8 hours of onset, followed by five 100 mg subcutaneous injections every 12 hours)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (matched to anakinra treatment)
Number of subjects: 25
Study: 37452734

Group type: EXPERIMENTAL
Intervention: High-resolution magnetic resonance imaging (HR-MRI)
Number of subjects: 168
Study: 37452805

Group type: EXPERIMENTAL
Intervention: Ketone Ester (KE)
Number of subjects: 12
Study: 37452849

Group type: EXPERIMENTAL
Intervention: SIBP04 (bevacizumab biosimilar) combined with carboplatin and paclitaxel
Number of subjects: 398
Study: 37452882

Group type: EXPERIMENTAL
Intervention: 10 synchronous, virtual CBSM group sessions immediately (n=41)
Number of subjects: 75

Group type: COMPARATOR
Intervention: 10 synchronous, virtual CBSM group sessions after a 6-month waitlist (n=34)
Number of subjects: 75
Study: 37452894

Group type: EXPERIMENTAL
Intervention: Extended Knee Control
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Adductor strength programme
Number of subjects: 502

Group type: COMPARATOR
Intervention: Comparison group (self-chosen IPEP)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 502

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 502
Study: 37452974

Group type: EXPERIMENTAL
Intervention: Desarda hernioplasty
Number of subjects: 110

Group type: COMPARATOR
Intervention: Lichtenstein hernioplasty
Number of subjects: 110
Study: 37453138

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 37453242

Group type: EXPERIMENTAL
Intervention: 3D-CNN
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Dermatologists
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Augmented Intelligence
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 2D-CNN
Number of subjects: 143

Group type: COMPARATOR
Intervention: Gold standard
Number of subjects: 143
Study: 37453249

Group type: EXPERIMENTAL
Intervention: Multimodal home care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard home care)
Number of subjects: 0
Study: 37453361

Group type: EXPERIMENTAL
Intervention: Third vaccine dose
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Fourth vaccine dose
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Three doses and infection
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Three and four vaccine doses
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Specific primary immunodeficiencies and immunosuppressive medication
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Overall study findings
Number of subjects: 356
Study: 37453367

Group type: EXPERIMENTAL
Intervention: Onconum software platform for extracting and structuring information from electronic health records (EHRs) using machine learning and natural language processing techniques.
Number of subjects: 9599
Study: 37453445

Group type: EXPERIMENTAL
Intervention: Ultra-low tidal volume (ULTV) ventilation
Number of subjects: 215

Group type: COMPARATOR
Intervention: Low tidal volume (LTV) ventilation
Number of subjects: 215
Study: 37453536

Group type: EXPERIMENTAL
Intervention: CT-FFR with a coarse-to-fine subpixel algorithm
Number of subjects: 316

Group type: COMPARATOR
Intervention: CCTA >50% stenosis
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: CT-FFR
Number of subjects: 316

Group type: COMPARATOR
Intervention: CCTA
Number of subjects: 316
Study: 37453736

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 1969

Group type: COMPARATOR
Intervention: QQ genotype
Number of subjects: 1969
Study: 37453737

Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate (n = 310)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Abatacept monotherapy (n = 99)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Abatacept monotherapy
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Abatacept + Methotrexate and Abatacept monotherapy
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 409

Group type: COMPARATOR
Intervention: Baseline Methotrexate
Number of subjects: 409
Study: 37453996

Group type: EXPERIMENTAL
Intervention: Automatic segmentation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Comparison of automatic vs manual segmentation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation with hepatotoxicity
Number of subjects: 31
Study: 37454014

Group type: EXPERIMENTAL
Intervention: 3 months of preoperative endocrine therapy (pre-ET)
Number of subjects: 37
Study: 37454148

Group type: EXPERIMENTAL
Intervention: 1 g of marine omega-3 FA per day (460 mg eicosapentanoic acid and 380 mg docosahexaenoic acid) and 2000 IU Vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37454162

Group type: EXPERIMENTAL
Intervention: Spectral multiphasic CT Angiography (mCTA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CT Angiography (mCTA)
Number of subjects: 31
Study: 37454537

Group type: EXPERIMENTAL
Intervention: Fluorouracil and folinic acid with panitumumab (Pmab) as maintenance therapy
Number of subjects: 377

Group type: COMPARATOR
Intervention: Fluorouracil and folinic acid without panitumumab (Pmab) as maintenance therapy
Number of subjects: 377
Study: 37454728

Group type: EXPERIMENTAL
Intervention: CLARO+ intervention including overdose prevention, recognition and response training, lethal means safety counseling, and Caring Contacts.
Number of subjects: 0

Group type: COMPARATOR
Intervention: CLARO intervention (baseline intervention without additional components).
Number of subjects: 0
Study: 37454733

Group type: EXPERIMENTAL
Intervention: CHW+
Number of subjects: 31

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 31
Study: 37454754

Group type: EXPERIMENTAL
Intervention: Centralized clinical support pathway intervention directed by population health coordinators
Number of subjects: 600
Study: 37454762

Group type: EXPERIMENTAL
Intervention: High flow oxygen (HFO) > 6 l/minute
Number of subjects: 448

Group type: COMPARATOR
Intervention: Low flow oxygen (LFO) ≤ 6 litres/minute
Number of subjects: 448

Group type: COMPARATOR
Intervention: No supplemental oxygen (NSO)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Remdesivir initiation ≥ 2 days after admission
Number of subjects: 448
Study: 37454789

Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) solution
Number of subjects: 148

Group type: COMPARATOR
Intervention: 5% potassium nitrate solution (control)
Number of subjects: 148
Study: 37455151

Group type: EXPERIMENTAL
Intervention: Virtual Reality
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 74
Study: 37455214

Group type: EXPERIMENTAL
Intervention: Sunitinib and Gemcitabine (SG)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sunitinib alone (S)
Number of subjects: 85
Study: 37455237

Group type: EXPERIMENTAL
Intervention: 14-day AZLI (75 mg three times daily for 14 days)
Number of subjects: 149

Group type: COMPARATOR
Intervention: 28-day AZLI (75 mg three times daily for 28 days)
Number of subjects: 149
Study: 37455345

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Allogeneic haematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 38
Study: 37455355

Group type: EXPERIMENTAL
Intervention: QFR+/AMR+ group
Number of subjects: 942

Group type: COMPARATOR
Intervention: QFR-/AMR- group
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: CFV < 17.4 cm/s
Number of subjects: 942

Group type: COMPARATOR
Intervention: CFV ≥ 17.4 cm/s
Number of subjects: 942
Study: 37455404

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray (Valtoco) as rescue therapy for seizure clusters
Number of subjects: 64
Study: 37455496

Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg i.v. on day 1 and 15, Q2W) plus TAS-102 (35 mg/m²)
Number of subjects: 0